Consider that the Institute for Clinical and Economic Review (ICER) identified that for GLP-1s to reflect cost-effective pricing in these targeted populations, it would require these drugs to be priced at an annual cost of $7,500, approximately one-third of the actual list price
Semaglutide demonstrated significant reductions in major adverse cardiovascular events in SUSTAIN-6 and, more recently, in non-diabetic patients with established CVD in the SELECT trial [3,22,23]
Its easy to group all sexual health treatments together, but PT-141 stands in a category of its own, especially when compared to hormone therapy
[1] [16] When treatment is interrupted, these beneficial effects gradually diminish
Heterogeneity was quantified with the I-squared statistic